VOLORIDGE INVESTMENT MANAGEMENT, LLC


Voloridge Investment Management, LLC, a Florida limited liability company, (the “Company”, the “�irm”, “we”, “us” or “our”) is a quantitative investment manager founded by David Vogel in 2009. The �irm is registered as an investment adviser with the United States Securities and Exchange Commission (“SEC”). The Company is controlled by the following persons:
Name Title CRD#
David S. Vogel Manager, CEO and Chief Scientist 5750880 Barry S. Miller Manager and President 2729056 Sean M. Hayes Manager and VP of Business Development 5866555 Our mission is to deliver superior risk-adjusted returns driven by an entrepreneurial environment that inspires unyielding passion, imagination and commitment to excellence. Our proprietary investment strategies are designed to calculate risk and probability with the overall objective of preserving assets while delivering appreciation regardless of the performance of broad �inancial markets. In January 2020, the �irm launched its third multi strategy program, VSF complex, that allocates capital to strategies developed and managed by the �irm. Similarly to the existing programs, this master-feeder fund complex has two feeder funds: VSF, LP, a Delaware limited partnership, and VSF, Ltd a Cayman Islands exempted company. VSF, LP and VSF, Ltd will contribute all of their investible assets to VSF Master, LP (“Intermediate Fund”), a Cayman Islands exempted limited partnership. The Intermediate Fund will invest all of its investible assets to Voloridge ESG Fund Master, LP (“ESG Master”), a Cayman Islands exempted limited partnership and Voloridge CC Fund Master, LP (“CC Master”), a Cayman Islands exempted limited partnership, in the aggregate. Initially, this program will allocate capital to four strategies including a customized ESG version of our intermediate-term US equity market neutral strategy through ESG Master and three climate change strategies through CC Master. The standard version of the intermediate-term US equity market neutral strategy has been used by VF Master, which is the master fund of the Voloridge Fund complex. Additional strategies are intended to be added over time. Investors will be able to invest in VSF, LP and VSF, Ltd. The �irm has two existing multi strategy programs, VF complex and VTAF complex, that allocates capital to strategies developed and managed by the �irm. Each master-feeder fund complex has two feeder funds. Investors may invest in the feeder funds, which will in turn invest directly into their master funds, respectively. The VF complex’s feeder funds: Voloridge Fund, LP (“VF, LP”), a Delaware limited partnership, and Voloridge Fund, Ltd. (“VF, Ltd.”), a Cayman Islands exempted company, will invest directly into the Voloridge Fund Master, LP (“VF Master”), a Cayman Islands exempted limited partnership. The VTAF complex’s feeder funds: Voloridge Trading Aggressive Fund, LP, (“VTAF, LP”), a Delaware limited partnership, and Voloridge Trading Aggressive Fund, Ltd., (“VTAF, Ltd.”) a Cayman Islands exempted company, will invest directly into the Voloridge Trading Fund Master, LP, (“VTF Master”), a Cayman Islands exempted limited partnership. The VF complex allocates capital to an intermediate-term US equity market neutral and a global futures strategy. The VTAF complex allocates capital to a short-term and intermediate- term US equity market neutral and global futures strategy. The return pro�ile of the strategies is designed PART 2A OF FORM ADV Page 5 of 17 with the goal of delivering an attractive risk/return relationship when compared to other investment alternatives. Investors will be able to invest in VF, LP, VF, Ltd., VTAF, LP, and VTAF, Ltd. VTAF, LP, VTAF, Ltd., VF, LP, VF, Ltd., VSF, LP, and VSF, Ltd., may be referred to individually as a Fund and collectively as the Funds. VTF Master, VF Master, ESG Master and CC Master may be referred to individually as the Master Fund and collectively as the Master Funds. VTAF, LP, VF, LP, and VSF, LP are primarily suitable for US taxable investors, while VTAF, Ltd., VF, Ltd., and VSF, Ltd. are primarily suitable for US tax exempt investors and non-US investors. The �irm also has a proprietary fund, Voloridge Global Fund, LP, (“VGF, LP”), a Delaware limited partnership, and provides advisory services to one separately managed account. As of December 31, 2019, our regulatory assets under management totaled: $10.08 billion. We do not offer non-discretionary investment management services. please register to get more info

Open Brochure from SEC website
Assets
Pooled Investment Vehicles $9,444,577,324
Discretionary $10,084,130,104
Non-Discretionary $
Registered Web Sites

Related news

Seres Therapeutics (NASDAQ:MCRB) Upgraded by Zacks Investment Research to “Hold”

Seres Therapeutics (NASDAQ:MCRB) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday, Zacks.com reports. According to Zacks, “Seres Therapeutics,

New Fortress Energy (NASDAQ:NFE) Upgraded to “Hold” at Zacks Investment Research

New Fortress Energy (NASDAQ:NFE) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.

Sei Investments Co. Increases Stake in GrafTech International Ltd. (NYSE:EAF)

Sei Investments Co. grew its stake in GrafTech International Ltd. (NYSE:EAF) by 13.7% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 66,600 shares of the company’s stock after buying an additional 8,

Voloridge Investment Management LLC Purchases Shares of 28,211 Meredith Co. (NYSE:MDP)

Voloridge Investment Management LLC acquired a new position in shares of Meredith Co. (NYSE:MDP) during the third quarter, Holdings Channel reports. The institutional investor acquired 28,211 shares of the company’s stock,

Hedge funds sold Moderna, BioNtech shares before vaccine news

BOSTON (Reuters) - A number of hedge funds sold positions in two drug companies leading the race to a coronavirus vaccine in the quarter before both announced breakthroughs that lifted their stock ...

Hedge funds sold Moderna, BioNtech shares before vaccine news

A number of hedge funds sold positions in two drug companies leading the race to a coronavirus vaccine in the quarter before both announced breakthroughs that lifted their stock prices, while a ...
Loading...
No recent news were found.